Heme: Modulator of Plasma Systems in Hemolytic Diseases

Trends in Molecular Medicine

Volumn 22, Issue 3, 2016, Pages 200-213

  Roumenina, Lubka T ^a,b,c   Rayes, Julie ^d   Lacroix Desmazes, Sébastien ^a,b,c   Dimitrov, Jordan D ^a,b,c  

^a SORBONNE UNIVERSITÉ   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Coagulation; Complement; Heme; Hemolytic disorders; Immunoglobulins

Indexed keywords

COMPLEMENT; HEME; IMMUNOGLOBULIN; PLASMA PROTEIN;

BETA THALASSEMIA; BLOOD CLOTTING; COMPLEMENT SYSTEM; ENDOTHELIUM; ERYTHROCYTE; HEMOLYSIS; HEMOLYTIC ANEMIA; HEMOSTASIS; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; INFLAMMATION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PLASMA; REVIEW; SICKLE CELL ANEMIA; ANIMAL; BLOOD; IMMUNOLOGY; PATHOLOGY;

ANEMIA, HEMOLYTIC; ANIMALS; COMPLEMENT SYSTEM PROTEINS; HEME; HEMOSTASIS; HUMANS; IMMUNOGLOBULINS;

EID: 84959086910     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2016.01.004     Document Type: Review

References (123)

1. Zhang L., Guarente L. Heme binds to a short sequence that serves a regulatory function in diverse proteins. EMBO J. 1995, 14:313-320.
2. Tang X.D., et al. Haem can bind to and inhibit mammalian calcium-dependent Slo1 BK channels. Nature 2003, 425:531-535.
3. Kaasik K., Lee C.C. Reciprocal regulation of haem biosynthesis and the circadian clock in mammals. Nature 2004, 430:467-471.
4. Raghuram S., et al. Identification of heme as the ligand for the orphan nuclear receptors REV-ERBalpha and REV-ERBbeta. Nat. Struct. Mol. Biol. 2007, 14:1207-1213.
5. Kuhl T., Imhof D. Regulatory Fe(II/III) heme: the reconstruction of a molecule's biography. Chembiochem 2014, 15:2024-2035.
6. Kumar S., Bandyopadhyay U. Free heme toxicity and its detoxification systems in human. Toxicol. Lett. 2005, 157:175-188.
7. Schaer D.J., et al. Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood 2013, 121:1276-1284.
8. Hebbel R.P., et al. Accelerated autoxidation and heme loss due to instability of sickle hemoglobin. Proc. Natl. Acad. Sci. U.S.A. 1988, 85:237-241.
9. Umbreit J. Methemoglobin - it's not just blue: a concise review. Am. J. Hematol. 2007, 82:134-144.
10. Balla J., et al. Endothelial-cell heme uptake from heme proteins: induction of sensitization and desensitization to oxidant damage. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:9285-9289.
11. Wagener F.A., et al. Heme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase. Blood 2001, 98:1802-1811.
12. Wagener F.A., et al. Different faces of the heme-heme oxygenase system in inflammation. Pharmacol. Rev. 2003, 55:551-571.
13. Ascenzi P., et al. Hemoglobin and heme scavenging. IUBMB Life 2005, 57:749-759.
14. Chiabrando D., et al. Heme in pathophysiology: a matter of scavenging, metabolism and trafficking across cell membranes. Front. Pharmacol. 2014, 5:61.
15. Ascenzi P., Fasano M. Serum heme-albumin: an allosteric protein. IUBMB Life 2009, 61:1118-1122.
16. Baek J.H., et al. Hemoglobin-driven pathophysiology is an in vivo consequence of the red blood cell storage lesion that can be attenuated in guinea pigs by haptoglobin therapy. J. Clin. Invest. 2012, 122:1444-1458.
17. Smith A., McCulloh R.J. Hemopexin and haptoglobin: allies against heme toxicity from hemoglobin not contenders. Front. Physiol. 2015, 6:187.
18. Vinchi F., et al. Hemopexin therapy improves cardiovascular function by preventing heme-induced endothelial toxicity in mouse models of hemolytic diseases. Circulation 2013, 127:1317-1329.
19. Deuel J.W., et al. Different target specificities of haptoglobin and hemopexin define a sequential protection system against vascular hemoglobin toxicity. Free Rad. Biol. Med. 2015, 89:931-943.
20. Muller-Eberhard U., et al. Plasma concentrations of hemopexin, haptoglobin and heme in patients with various hemolytic diseases. Blood 1968, 32:811-815.
21. Sears D.A. Disposal of plasma heme in normal man and patients with intravascular hemolysis. J. Clin. Invest. 1970, 49:5-14.
22. Adams P.A., Berman M.C. Kinetics and mechanism of the interaction between human serum albumin and monomeric haemin. Biochem. J. 1980, 191:95-102.
23. Larsson J., et al. The lipocalin alpha1-microglobulin binds heme in different species. Arch. Biochem. Biophys. 2004, 432:196-204.
24. Camus S.M., et al. Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vaso-occlusions in sickle cell disease. Blood 2015, 125:3805-3814.
25. Gozzelino R., et al. Mechanisms of cell protection by heme oxygenase-1. Annu. Rev. Pharmacol. Toxicol. 2010, 50:323-354.
26. Figueiredo R.T., et al. Characterization of heme as activator of Toll-like receptor 4. J. Biol. Chem. 2007, 282:20221-20229.
27. Belcher J.D., et al. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood 2014, 123:377-390.
28. Dutra F.F., et al. Hemolysis-induced lethality involves inflammasome activation by heme. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:E4110-E4118.
29. Cappellini M.D. Coagulation in the pathophysiology of hemolytic anemias. Hematology 2007, 74-78.
30. Lim M.Y., et al. Hemostatic abnormalities in sickle cell disease. Curr. Opin. Hematol. 2013, 20:472-477.
31. Angchaisuksiri P. Coagulopathy in malaria. Thromb. Res. 2014, 133:5-9.
32. Ghosh S., et al. Extracellular hemin crisis triggers acute chest syndrome in sickle mice. J. Clin. Invest. 2013, 123:4809-4820.
33. Frimat M., et al. Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. Blood 2013, 122:282-292.
34. Rayes J., et al. The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status. Blood 2014, 123:121-125.
35. Neely S.M., et al. Effect of hematin on endothelial cells and endothelial cell-platelet interactions. Am. J. Pathol. 1984, 115:390-396.
36. Lu R.N., et al. Unconjugated bilirubin inhibits proteolytic cleavage of von Willebrand factor by ADAMTS13 protease. J. Thromb. Haemost. 2015, 13:1064-1072.
37. Green D., et al. The interaction of the factor VIII/von Willebrand factor complex with hematin. Thromb. Haemost. 1986, 56:277-282.
38. Glueck R., et al. Hematin: unique effects of hemostasis. Blood 1983, 61:243-249.
39. Neely S.M., et al. Mechanism and characteristics of platelet activation by haematin. Br. J. Haematol. 1984, 58:305-316.
40. McColl K.E., et al. Treatment with haematin in acute hepatic porphyria. Quart. J. Med. 1981, 50:161-174.
41. Morris D.L., et al. Coagulopathy associated with hematin treatment for acute intermittent porphyria. Ann. Intern. Med. 1981, 95:700-701.
42. Repesse Y., et al. Heme binds to factor VIII and inhibits its interaction with activated factor IX. J. Thromb. Haemost. 2012, 10:1062-1071.
43. Lenting P.J., et al. The life cycle of coagulation factor VIII in view of its structure and function. Blood 1998, 92:3983-3996.
44. Nielsen V.G., et al. Fibrinogen is a heme-associated, carbon monoxide sensing molecule: a preliminary report. Blood Coagul. Fibrinolysis 2011, 22:443-447.
45. Green D., et al. The inactivation of hemostatic factors by hematin. J. Lab. Clin. Med. 1983, 102:361-369.
46. Simionatto C.S., et al. Thrombophlebitis and disturbed hemostasis following administration of intravenous hematin in normal volunteers. Am. J. Med. 1988, 85:538-540.
47. Jones R.L. Hematin-derived anticoagulant. Generation in vitro and in vivo. J. Exp. Med. 1986, 163:724-739.
48. Volin L., et al. Heme arginate: effects on hemostasis. Blood 1988, 71:625-628.
49. Green D., Ts'ao C.H. Hematin: effects on hemostasis. J. Lab. Clin. Med. 1990, 115:144-147.
50. Setty B.N., et al. Heme induces endothelial tissue factor expression: potential role in hemostatic activation in patients with hemolytic anemia. J. Thromb. Haemost. 2008, 6:2202-2209.
51. Sparkenbaugh E.M., et al. Excess of heme induces tissue factor-dependent activation of coagulation in mice. Haematologica 2015, 100:308-314.
52. McIntyre J.A. The appearance and disappearance of antiphospholipid autoantibodies subsequent to oxidation-reduction reactions. Thromb. Res. 2004, 114:579-587.
53. McIntyre J.A., et al. Autoantibodies unmasked by redox reactions. J. Autoimmun. 2005, 24:311-317.
54. Omersel J., et al. Autoimmune reactivity of IgM acquired after oxidation. Redox. Rep. 2011, 16:248-256.
55. McIntyre J.A., et al. Redox-reactive autoantibodies: detection and physiological relevance. Autoimmun. Rev. 2006, 5:76-83.
56. Dimitrov J.D., et al. Antibodies use heme as a cofactor to extend their pathogen elimination activity and to acquire new effector functions. J. Biol. Chem. 2007, 282:26696-26706.
57. McIntyre J.A., Faulk A.W. Autoantibody potential of cancer therapeutic monoclonal antibodies. Int. J. Cancer 2010, 127:491-496.
58. Dimitrov J.D., et al. A cryptic polyreactive antibody recognizes distinct clades of HIV-1 glycoprotein 120 by an identical binding mechanism. J. Biol. Chem. 2014, 289:17767-17779.
59. McIntyre J.A., Faulk W.P. Redox-reactive autoantibodies: biochemistry, characterization, and specificities. Clin. Rev. Allergy Immunol. 2009, 37:49-54.
60. Hadzhieva M., et al. Mechanism and functional implications of the heme-induced binding promiscuity of IgE. Biochemistry 2015, 54:2061-2072.
61. Lecerf M., et al. Prevalence and gene characteristics of antibodies with cofactor-induced HIV-1 specificity. J. Biol. Chem. 2015, 290:5203-5213.
62. Gupta N., et al. Neutralization of Japanese encephalitis virus by heme-induced broadly reactive human monoclonal antibody. Sci. Rep. 2015, 5:16248.
63. Mahendra A., et al. Cryptic polyreactivity of IgG expressed by splenic marginal zone B-cell lymphoma. Mol. Immunol. 2014, 60:54-61.
64. Dimitrov J.D., et al. Ferrous ions and reactive oxygen species increase antigen-binding and anti-inflammatory activities of immunoglobulin G. J. Biol. Chem. 2006, 281:439-446.
65. Dimitrov J.D., et al. Heterogeneous antigen recognition behavior of induced polyspecific antibodies. Biochem. Biophys. Res. Commun. 2010, 398:266-271.
66. Wedemayer G.J., et al. Structural insights into the evolution of an antibody combining site. Science 1997, 276:1665-1669.
67. Arnout J., Jankowski M. Thrombosis - Fundamental and Clinical Aspects 2003, Leuven University Press.
68. McIntyre J.A., et al. Redox-reactive autoantibodies in cerebrospinal fluids. Ann. N.Y. Acad. Sci. 2007, 1109:296-302.
69. McIntyre J.A., et al. Redox-reactive antiphospholipid antibody differences between serum from Alzheimer's patients and age-matched controls. Autoimmunity 2009, 42:646-652.
70. McIntyre J.A., et al. Antiphospholipid autoantibodies as blood biomarkers for detection of early stage Alzheimer's disease. Autoimmunity 2015, 48:344-351.
71. Pavlovic S., et al. Intravenous immunoglobulins exposed to heme (heme IVIG) are more efficient than IVIG in attenuating autoimmune diabetes. Clin. Immunol. 2011, 138:162-171.
72. de Ciutiis A., et al. Immunologic defect of the alternate pathway-of-complement activation postsplenectomy: a possible relation between splenectomy and infection. J. Natl. Med. Assoc. 1978, 70:667-670.
73. Mold C., et al. Complement activation during painful crisis in sickle cell anemia. Clin. Immunol. Immunopathol. 1995, 76:314-320.
74. Biryukov S., Stoute J.A. Complement activation in malaria: friend or foe?. Trends Mol. Med. 2014, 20:293-301.
75. Becker C.G., et al. Activation of factor XII-dependent pathways in human plasma by hematin and protoporphyrin. J. Clin. Invest. 1985, 76:413-419.
76. Smith D.J., Winslow R.M. Effects of extraerythrocytic hemoglobin and its components on mononuclear cell procoagulant activity. J. Lab. Clin. Med. 1992, 119:176-182.
77. Pawluczkowycz A.W., et al. Hematin promotes complement alternative pathway-mediated deposition of C3 activation fragments on human erythrocytes: potential implications for the pathogenesis of anemia in malaria. J. Immunol. 2007, 179:5543-5552.
78. Jakeman G.N., et al. Anaemia of acute malaria infections in non-immune patients primarily results from destruction of uninfected erythrocytes. Parasitology 1999, 119:127-133.
79. Moreno A., et al. Plasmodium coatneyi in rhesus macaques replicates the multisystemic dysfunction of severe malaria in humans. Infect. Immun. 2013, 81:1889-1904.
80. Hillmen P., et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. New Engl. J. Med. 2006, 355:1233-1243.
81. Risitano A.M., et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood 2009, 113:4094-4100.
82. Lin Z., et al. Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria. Blood 2015, 126:891-894.
83. Anderson N.L., Anderson N.G. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 2002, 1:845-867.
84. Del Conde I., et al. Platelet activation leads to activation and propagation of the complement system. J. Exp. Med. 2005, 201:871-879.
85. Morigi M., et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J. Immunol. 2011, 187:172-180.
86. Merle N.S., et al. Complement system part II. Role in immunity. Front. Immunol. 2015, 6:257.
87. Chudwin D.S., et al. Increased activation of the alternative complement pathway in sickle cell disease. Clin. Immunol. Immunopathol. 1985, 37:93-97.
88. Silver K.L., et al. Complement driven innate immune response to malaria: fuelling severe malarial diseases. Cell. Microbiol. 2010, 12:1036-1045.
89. Dimitrov J.D., et al. Iron ions and haeme modulate the binding properties of complement subcomponent C1q and of immunoglobulins. Scand. J. Immunol. 2007, 65:230-239.
90. Roumenina L.T., et al. Heme interacts with c1q and inhibits the classical complement pathway. J. Biol. Chem. 2011, 286:16459-16469.
91. Merle N.S., et al. Complement system part I. Molecular mechanisms of activation and regulation. Front. Immunol. 2015, 6:262.
92. Jeney V., et al. Red blood cell, hemoglobin and heme in the progression of atherosclerosis. Front. Physiol. 2014, 5:379.
93. Soares M.P., et al. Expression of heme oxygenase-1 can determine cardiac xenograft survival. Nat. Med. 1998, 4:1073-1077.
94. Kim J.H., et al. Heme oxygenase-1 protects rat kidney from ureteral obstruction via an antiapoptotic pathway. J. Am. Soc. Nephrol. 2006, 17:1373-1381.
95. Correa-Costa M., et al. Transcriptome analysis of renal ischemia/reperfusion injury and its modulation by ischemic pre-conditioning or hemin treatment. PLoS ONE 2012, 7:e49569.
96. Andreas M., et al. Heme arginate improves reperfusion patterns after ischemia: a randomized, placebo-controlled trial in healthy male subjects. J. Cardiovas. Magn. Res. 2012, 14:55.
97. Thomas R.A., et al. Hemin preconditioning upregulates heme oxygenase-1 in deceased donor renal transplant recipients: a randomized, controlled, phase IIB trial. Transplantation 2016, 100:176-183.
98. Dekker D., et al. Vascular and metabolic effects of the haem oxygenase-1 inducer haem arginate in subjects with the metabolic syndrome: a translational cross-over study. Diabetes Vasc. Dis. Res. 2016, 13:41-48.
99. Burgess A., et al. Adipocyte heme oxygenase-1 induction attenuates metabolic syndrome in both male and female obese mice. Hypertension 2010, 56:1124-1130.
100. Ndisang J.F., Jadhav A. Hemin therapy suppresses inflammation and retroperitoneal adipocyte hypertrophy to improve glucose metabolism in obese rats co-morbid with insulin-resistant type-2 diabetes. Diabetes Obes. Metabol. 2013, 15:1029-1039.
101. Alam M.S., et al. Plasma signature of neurological disease in the monogenetic disorder Niemann-Pick type C. J. Biol. Chem. 2014, 289:8051-8066.
102. Hada H., et al. Hemopexin-dependent heme uptake via endocytosis regulates the Bach1 transcription repressor and heme oxygenase gene activation. Biochim. Biophys. Acta 2014, 1840:2351-2360.
103. Larsen R., et al. Heme cytotoxicity and the pathogenesis of immune-mediated inflammatory diseases. Front. Pharmacol. 2012, 3:77.
104. Dong B., et al. Hemopexin induces neuroprotection in the rat subjected to focal cerebral ischemia. BMC Neurosci. 2013, 14:58.
105. Smith L.J., et al. Heme proteins - diversity in structural characteristics, function, and folding. Proteins 2010, 78:2349-2368.
106. Cederlund M., et al. A1 M/alpha1-microglobulin is proteolytically activated by myeloperoxidase, binds its heme group and inhibits low density lipoprotein oxidation. Front. Physiol. 2015, 6:11.
107. Miller Y.I., Shaklai N. Kinetics of hemin distribution in plasma reveals its role in lipoprotein oxidation. Biochim. Biophys. Acta 1999, 1454:153-164.
108. Joerk A., et al. Impact of heme and heme degradation products on vascular diameter in mouse visual cortex. J. Am. Heart Assoc. 2014, 3:e001220.
109. Allhorn M., et al. Processing of the lipocalin alpha1-microglobulin by hemoglobin induces heme-binding and heme-degradation properties. Blood 2002, 99:1894-1901.
110. Tolosano E., et al. Defective recovery and severe renal damage after acute hemolysis in hemopexin-deficient mice. Blood 1999, 94:3906-3914.
111. Larsen R., et al. A central role for free heme in the pathogenesis of severe sepsis. Sci. Transl. Med. 2010, 2:51ra71.
112. Novogrodsky A., et al. Immune stimulatory properties of metalloporphyrins. J. Immunol. 1989, 143:3981-3987.
113. Watanabe-Matsui M., et al. Heme regulates B-cell differentiation, antibody class switch, and heme oxygenase-1 expression in B cells as a ligand of Bach2. Blood 2011, 117:5438-5448.
114. Fortes G.B., et al. Heme induces programmed necrosis on macrophages through autocrine TNF and ROS production. Blood 2012, 119:2368-2375.
115. Zhong H., et al. Hemin controls T cell polarization in sickle cell alloimmunization. J. Immunol. 2014, 193:102-110.
116. Graca-Souza A.V., et al. Neutrophil activation by heme: implications for inflammatory processes. Blood 2002, 99:4160-4165.
117. Porto B.N., et al. Heme induces neutrophil migration and reactive oxygen species generation through signaling pathways characteristic of chemotactic receptors. J. Biol. Chem. 2007, 282:24430-24436.
118. Chen G., et al. Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease. Blood 2014, 123:3818-3827.
119. Kwon M.S., et al. Methemoglobin is an endogenous toll-like receptor 4 ligand-relevance to subarachnoid hemorrhage. Intl. J. Mol. Sci. 2015, 16:5028-5046.
120. Schallner N., et al. Microglia regulate blood clearance in subarachnoid hemorrhage by heme oxygenase-1. J. Clin. Invest. 2015, 125:2609-2625.
121. Pamplona A., et al. Heme oxygenase-1 and carbon monoxide suppress the pathogenesis of experimental cerebral malaria. Nat. Med. 2007, 13:703-710.
122. Ferreira A., et al. A central role for free heme in the pathogenesis of severe malaria: the missing link?. J. Mol. Med. 2008, 86:1097-1111.
123. Ricklin D., et al. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 2010, 11:785-797.